It was seen that HER2 negative and HER2 low patients have similar prognosis regardless of hormone receptor status [9, 12] but it was noted that HR-positive tumours with HER2 low status have better disease-free survival (DFS) rates than HR-positive/ HER2 negative [9]. The gene discussed is NR4A1; the disease is neoplasm.